The Kitchen is empty.
Arrow Exploration 19.75p £46.6m (AXL.L)
The high-growth operator with a portfolio of assets across key Colombian hydrocarbon basins, provides an update on the drilling of Carrizales Norte 1 (CN-1), an exploration well on the Tapir Block in the Llanos Basin of Colombia. The CN-1 well was spud on May 1, 2023 and reached total depth on May 11, 2023. The well was drilled to a total measured depth of 9,190 feet (8,511 feet true vertical depth) and encountered approximately 148 feet of net oil pay measured depth (128 feet TVD). The hydrocarbon bearing intervals are as follows: 26 feet of net pay in Carbonera C7 sands; 64 feet of net oil pay within the Gacheta formation; 58 feet net oil pay within the Ubaque formation. Tests will be conducted over the following weeks, with production forecast to commence in early June 2023. The Carrizales Norte-2 (CN-2) well will be drilled immediately upon completion of CN-1.
Autins Group 11p £6m (AUTG.L)
The UK and European manufacturer of the patented Neptune melt-blown material and specialist in the design, manufacture and supply of acoustic and thermal insulation solutions, announces the appointment of Andrew Burn as Non-Executive Director of the Company, effective immediately. Andrew is a chartered accountant and a fellow of the ICAEW. He spent over 20 years at KPMG where he was a partner and during COVID-19 was the Head of Automotive in the UK.
Critical Metals 25.5p £15.3m (CRTM.L)
The mining investment company established to acquire mining opportunities in the critical and strategic metals sector, provides an operational update on activities at the Company’s Molulu copper/cobalt asset in the Democratic Republic of Congo. The Company has mined over 6,500 tonnes of oxide ore at an average grade of 3%, which is available for sale. After surveying the Molulu copper grades, the mining focus is on the high-grade sulphide copper ore. Mining the sulphide zones has the potential to increase profitability by orders of magnitude above the oxide only mining. Mapping, geophysics, and IP (induced-polarisation) programmes are expected to be completed by the end of May, and the drilling programme will begin in June. A number of potential buyers of copper ore have recently visited Molulu and took samples for testing in their plants. First sales of oxide ore could commence as soon as the bridge is installed, and the road rehabilitation completed.
GENinCode 15.25p £14.6m (GENI.L)
The predictive genetics company focused on the prevention of cardiovascular disease, announces its collaboration with the University Clinic Dresden, Department of Internal Medicine and Department of Human Genetics, based in Germany, to use its LIPID inCode® test in primary care for the diagnosis of hypercholesterolemia (high levels of cholesterol) and familial hypercholesterolemia (FH). LIPID inCode® is the first polygenic product to be introduced in Germany to improve the diagnosis and treatment of hypercholesterolemia to prevent cardiovascular disease (CVD). LIPID inCode® testing will initially support the lipid centre in the region of Saxony to deliver its preventative care plans to identify individuals at risk of CVD. The collaboration follows the positive results of the LIPID inCode® Dresden clinical study and pilot.
Greenroc Mining 4.4p £5.9m (GROC.L)
A company focused on the development of critical mineral projects in Greenland, announces that it has awarded the contract to undertake a formal Preliminary Economic Assessment (PEA) for its Amitsoq Graphite Project to SLR Consulting Limited (SLR). SLR will commence work on the PEA in May 2023 and it is expected to be completed by September 2023. The completion of a PEA is an important step in the development of the Amitsoq Project towards commercial production. GreenRoc also announces that it has established a wholly owned Greenlandic registered subsidiary, Greenland Graphite a/s, to which the two graphite mineral exploration licences (2013-06 and 2022-03) currently owned by GreenRoc's subsidiary Obsidian Mining Ltd will be transferred, pending approval by the Greenland Government.
Instem 640p £146.4m (INS.L)
A provider of IT solutions to the global life sciences market, announces its audited results for the year ended 31 December 2022. Total Group revenues increased 28% to £58.9m (2021: £46.0m), with Software as a Service (SaaS) revenues increasing 41% to £13.7m (2021: £9.7m) and recurring revenues (annual support and SaaS) increased 43% to £34.5m (2021: £24.1m), 59% of total revenue (2021: 52%). Adjusted EBITDA increased 32% to £10.9m (2021: £8.3m), representing an adjusted EBITDA margin of 18.4% (2021: 17.9%). Cash balance as at 31 December 2022 of £14.0m (2021: £15.0m), after making deferred and contingent payments of £5.4m in 2022 in relation to the acquisitions made during 2021. Instem also announce that the Company has been granted exclusive rights to transition the ToxHub Platform from eTRANSAFE. The Platform has been designed to speed up the development of medicines, will be commercialised by Instem following integration into the Company's unique in silico suite, which it has rebranded as Centrus®. ToxHub will sit alongside the Company’s existing, data sharing, predictive modelling and insight generation solutions.
Journeo 175.5p £28.5m (JNEO.L)
The information systems and transport technical services group, announces that its recently acquired subsidiary, Infotec, has received a £0.9m purchase order for the manufacture and supply of passenger information displays for Northern Trains. On completion, this new purchase order will take the total number of displays supplied to Northern for their station upgrade to around 50% of its estate and the Directors consider that, due to the ongoing demand for Infotec's displays technology there is potential for additional revenue opportunities for the Company in 2024 and 2025 as Control Period 7 commences and Northern continues with the remainder of its station upgrade programme. The display systems are scheduled to enter production during H2 2023 with revenue recognised late in Q4 2023 and early Q1 2024 and are included in management's expectations of performance for FY2023.
Lexington Gold 9.25p £26.2m (LEX.L)
The gold exploration and development company with projects in North and South Carolina, USA, announce that, on 13 May 2023, it entered into, via its wholly owned recently incorporated subsidiary, conditional share subscription and loan agreements to acquire 76% of White Rivers Exploration Proprietary Limited (WRE) an exploration and development company with significant gold assets in South Africa. LEX has also entered into conditional loan assignment agreements with each of Mark Creasy and Sunswell Holdings Pty Ltd to acquire all of the outstanding loans they have historically made to WRE. The aggregate amount payable by the Company is £0.3m, by way of the provision of a subordinated loan to WRE, and up to £6.4m to be settled by way of the issue of new common shares in Lexington Gold.
Mirriad Advertising 3.45p £9.6m (MIRI.L)
The in-content advertising company, announces it has renewed a three-year agreement with Univision, the world's leader in Spanish language media and a top-10 US content supplier. The renewal additionally allows Mirriad to be the main sales channel for Univision's in-content placements. Univision is part of Mirriad's Multicultural Marketplace, a collection of film, television, streaming, digital and music content creators and companies.
Orcadian Energy 5p £3.6m (ORCA.L)
Orcadian announces that following extensive discussions with the North Sea Transition Authority (NSTA) that the NSTA has declined Orcadian's request to extend Phase A of Licence P2320. As a consequence the Licence determined (expired) on 14 May 2023. In addition, the potential disposals of interests in sub-areas of the licence to Rapid Oil and Carrick Resources will not now proceed. Orcadian has been in farm-out discussions with multiple counterparties regarding the drilling of an exploration well within the former P2320 licence area. Orcadian intends to make an out-of-round application for a new licence covering the extensions of the Pilot field into the P2320 area, the Blakeney and Feugh discoveries, and the prospects identified using the TGS seismic data and Quantitative Interpretation products. Licence P2244 (the Pilot field) remains the Company's key asset and key focus; and the Company's interest in this licence is unaffected by the NSTA decision on Licence P2320.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
